secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevance Health, Inc. (ELV)
CIK:        0001156039
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001156039-25-000142
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elevance Health elects Amy Schulman as independent director effective Jan 12, 2026
--------------------------------------------------------------------------------

- Amy Schulman, Managing Partner at Polaris Partners, joins Elevance Health board.
- Appointed to Audit and Finance Committees; effective January 12, 2026.
- Schulman also chairs Alnylam Pharmaceuticals board and is senior lecturer at Harvard Business School.
- Board cites ongoing refreshment strategy; Schulman brings healthcare, governance, and investment expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1156039/000115603925000142/0001156039-25-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1156039/000115603925000142/elv-20251210.htm
  HTML page:      https://secwatch.observer/filing/0001156039-25-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer